How are we creating fluoroquinolone-resistant tuberculosis?

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 4, 2009, Pages 288-289

  Bernardo, John ^a   Wing, Wai Yew ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; EDITORIAL; HUMAN; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EMPIRICISM; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; RETREATMENT; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 68849085388     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200906-0863ED     Document Type: Editorial

References (16)

1. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency Update; 2008 [accessed June 10, 2009]. Available from: http://whqlibdoc.who.int/publications/2008/9789241547581-eng.pdf
3. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338.
4. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised controlled phase II trial. Lancet 2009;373:1183-1189.
5. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-280.
6. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009;13:79-83.
7. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744-751.
8. Grimaldo ER, Tupasi TE, Rivera AB, Quelapio MI, Cardano RC, Derilo JO, Belen VA. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001;5:546-550.
9. Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Lew WJ, Koh Y, Kim WS, Kim DS, Kim WD, et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007;11:319-324.
10. Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese Medical Centre: 1995-2003. J Antimicrob Chemother 2005;56:1058-1062.
11. Wang J-Y, Hsueh P-R, Jan I-S, Lee L-N, Liaw Y-S, Yang P-C, Luh K-T. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006;61:903-908.
12. Long R, Chong H, Hoeppner V, Shanmuganathan H, Kowalewska-Grochowska K, Shandro C, Manfreda J, Senthilselvan A, Elzainy A, Marrie T. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone- resistant tuberculosis. Clin Infect Dis 2009;48:1354-1360.
13. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, Smith T, Hooper N, Maruri F, Warkentin J, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180:365-370.
14. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
15. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004;190:1642-1651.
16. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-612.